September 15, 2016 09:54 AM EDTUpdated September 18, 06:50 PM
R&D

Mer­ck, Pfiz­er tout PhI­II di­a­betes da­ta as er­tugli­fozin heads to the FDA

Arsalan Arif

Founder

Mer­ck and Pfiz­er rolled out pos­i­tive Phase III da­ta for their SGLT2 di­a­betes drug er­tugliflozin at the an­nu­al EASD meet­ing in Ger­many to­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times